Levodopa

Levodopa is a metabolic precursor to the neurotransmitter dopamine. It crosses the blood-brain barrier and is converted into dopamine, replenishing depleted levels in the brains of individuals with Parkinson's disease. This action directly alleviates motor symptoms like tremors, rigidity, and slowness of movement, making it the most effective symptomatic therapy for the condition.

Verdict

Essential for Parkinson's treatment; inappropriate and risky for healthspan purposes.

Protocol

• Initial doses are typically low, around 50-100 mg taken 1-3 times per day.
• Dosage is gradually titrated upwards by a physician based on clinical response and side effects.
• Almost always co-administered with a DOPA decarboxylase inhibitor like carbidopa or benserazide to increase efficacy and reduce side effects.

Flags

• Long-term use is associated with motor complications, including dyskinesias (involuntary movements) and 'on-off' fluctuations.
• Common side effects include nausea, dizziness, and orthostatic hypotension.
• May cause psychiatric side effects such as hallucinations, confusion, and impulse control disorders.
• Should not be used for any healthspan purpose due to its significant side effect profile.
• Interacts with non-selective MAO inhibitors, antipsychotics, and certain antihypertensives.